KalVista Pharmaceuticals (KALV) Change in Accured Expenses (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Change in Accured Expenses data on file, last reported at -$8.2 million in Q3 2025.

• For the quarter ending Q3 2025, Change in Accured Expenses fell 361.66% year-over-year to -$8.2 million; the trailing twelve-month figure through Jul 2025 stood at $3.2 million (up 18.86% YoY), and the FY2025 full-year result was $14.4 million, up 349.64% from the prior year.
• Change in Accured Expenses declined to -$8.2 million in Q3 2025, from $8.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.1 million in Q2 2025 to a low of -$8.2 million in Q3 2025.
• A 5-year average of $468777.8 and a median of $368000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 1154.11% in 2024 and soared 433.26% in 2025, its largest moves.
• Tracing KALV's Change in Accured Expenses over 5 years: stood at $217000.0 in 2021, then jumped by 374.19% to $1.0 million in 2022, then jumped by 290.09% to $4.0 million in 2023, then gained by 25.49% to $5.0 million in 2024, then sank by 262.78% to -$8.2 million in 2025.
• Business Quant data shows KALV's Change in Accured Expenses at -$8.2 million in Q3 2025, $8.1 million in Q2 2025, and $5.0 million in Q4 2024.